TechFlow News, July 23, according to PRNewswire, Nasdaq-listed company Canton Strategic Holdings announced that it has completed the sale transaction of its biotech R&D department Gravitas Life Sciences, with the buyer being Gravitas Collective Corp. The transaction was unanimously approved by the company's board of directors and was officially completed on July 17, 2026. This sale marks the company's further transformation into an operating company focused on promoting the digitization of traditional financial markets around the Canton Network, driving the process of asset tokenization and financial market digitization, as well as financial infrastructure business.
Add to Favorites
Share to Social Media




